RJA
PDSB icon

Raymond James & Associates’s PDS Biotechnology PDSB Stock Holding History

Raymond James & Associates’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$44.8K Sell
11,731
-2,121
-15% -$7.08K ﹤0.01% 3869
2024
Q2 		$40.6K Hold
13,852
– – ﹤0.01% 3815
2024
Q1 		$54.9K Sell
13,852
-10,509
-43% -$54.1K ﹤0.01% 3794
2023
Q4 		$121K Hold
24,361
– – ﹤0.01% 3620
2023
Q3 		$123K Buy
+24,361
New +$133K ﹤0.01% 3565
2016
Q3 		– Sell
-1,154
Closed -$233K – 3271
2016
Q2 		$233K Buy
+1,154
New +$204K ﹤0.01% 2565

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's PDSB Position: Q3 2024 in Review

Raymond James & Associates reduced its PDS Biotechnology (PDSB) stake by 15% in Q3 2024, selling an estimated $7.08K and leaving 11,731 shares worth $44.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3869.

Raymond James & Associates first reported a position in PDSB in Q2 2016 and has held it in 6 quarters since. The position peaked at $233K in Q2 2016. 57 funds tracked by Wall St. Rank hold PDSB as of Q3 2024.

  • Raymond James & Associates held 11,731 shares of PDS Biotechnology worth $44.8K as of Q3 2024.
  • Raymond James & Associates sold 2,121 PDS Biotechnology shares in Q3 2024, an estimated $7.08K.
  • PDS Biotechnology made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3869 holding.
  • Raymond James & Associates first reported a position in PDS Biotechnology in Q2 2016 and has held it in 6 quarters since.
  • Raymond James & Associates's PDS Biotechnology position peaked at $233K in Q2 2016.
  • 57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.